{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(6)"],"submitter":["Villanueva V"],"pubmed_abstract":["<h4>Objective</h4>This study investigated the effectiveness and tolerability of brivaracetam (BRV) monotherapy in a large series of patients with epilepsy.<h4>Method</h4>This was a multicenter, retrospective, observational, non-interventional study in 24 hospitals across Spain. Patients aged ≥18 years who started on BRV monotherapy, either as first-line or following conversion, at least 1 year before database closure were included. Patients were evaluated at baseline and at 3, 6 and 12 months after initiation of BRV monotherapy, in accordance with usual clinical practice at these centers. Data were collected retrospectively from patients' individual charts by participating physicians. The primary effectiveness and safety endpoints were the percentage of seizure-free patients 1 year after i"],"journal":["Epilepsia open"],"pagination":["2429-2442"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11633701"],"repository":["biostudies-literature"],"pubmed_title":["BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice."],"pmcid":["PMC11633701"],"pubmed_authors":["Zurita J","Lara LB","Hampel KG","Sierra-Marcos A","Estevez JC","Renau J","Barcelo MI","Martinez-Agredano P","Garcia-Escriva A","Gonzalez AM","Rubio-Roy M","de Toledo M","Fernandez-Cabrera A","Sansa G","Gomez-Ibanez A","Ojeda J","Alarcon C","Herrera JD","Mercedes-Alvarez B","Lopez-Gonzalez FJ","Parejo-Carbonell B","Villar EG","Rodriguez-Osorio X","Cabezas B","Monterde A","Villanueva V","Calle R","Martinez-Poles J","Rodriguez-Uranga J","Serratosa JM","Martinez E"],"additional_accession":[]},"is_claimable":false,"name":"BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice.","description":"<h4>Objective</h4>This study investigated the effectiveness and tolerability of brivaracetam (BRV) monotherapy in a large series of patients with epilepsy.<h4>Method</h4>This was a multicenter, retrospective, observational, non-interventional study in 24 hospitals across Spain. Patients aged ≥18 years who started on BRV monotherapy, either as first-line or following conversion, at least 1 year before database closure were included. Patients were evaluated at baseline and at 3, 6 and 12 months after initiation of BRV monotherapy, in accordance with usual clinical practice at these centers. Data were collected retrospectively from patients' individual charts by participating physicians. The primary effectiveness and safety endpoints were the percentage of seizure-free patients 1 year after i","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-04T02:33:19.019Z","creation":"2025-04-04T02:33:19.019Z"},"accession":"S-EPMC11633701","cross_references":{"pubmed":["39470722"],"doi":["10.1002/epi4.13078"]}}